Is it appropriate to reduce a patient's dose of Lyrica (pregabalin) from 75mg twice daily (bid) to 50mg bid when attempting to wean off the medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pregabalin Tapering: 75mg BID to 50mg BID

Yes, reducing from 75mg twice daily to 50mg twice daily is an appropriate and safe tapering step when weaning off pregabalin. This represents a 33% dose reduction, which aligns with established tapering principles for gabapentinoids.

Evidence-Based Tapering Protocol

The recommended tapering approach for pregabalin involves gradual dose reductions of 10-20% every 24-48 hours to minimize withdrawal symptoms 1. Your proposed reduction from 75mg BID (150mg/day total) to 50mg BID (100mg/day total) represents a 33% reduction, which is slightly more aggressive but remains within acceptable parameters for most patients 2.

Specific Tapering Schedule from Current Dose

Starting from 75mg twice daily (150mg/day):

  • Week 1: Reduce to 50mg twice daily (100mg/day) - this is your proposed step 2
  • Week 2: Reduce to 25mg twice daily (50mg/day) 2
  • Week 3: Discontinue or reduce to 25mg once daily if needed 2

The FDA label explicitly states that pregabalin should be tapered gradually over a minimum of 1 week when discontinuing 3. This minimum timeframe applies to the entire taper, not each dose reduction step.

Critical Monitoring Requirements

Monitor closely for withdrawal symptoms during each dose reduction, including headache, nausea, dizziness, insomnia, anxiety, and sweating 2. These symptoms typically emerge within 24-48 hours of dose reduction 1.

If withdrawal symptoms occur at the 50mg BID dose, extend the duration at this dose level to 2 weeks instead of 1 week before proceeding to the next reduction 2. This allows physiologic adaptation and minimizes distress.

Factors That May Require Slower Tapering

Renal Impairment

Elderly patients or those with renal dysfunction require more gradual tapering because pregabalin is 95% renally excreted unchanged 2, 3, 4. Calculate creatinine clearance before each dose reduction in patients over 65 years or with known kidney disease 2.

Duration of Therapy

Patients who have been on pregabalin for longer than 14 days typically require structured tapering protocols, while those on therapy less than 7 days can often discontinue more rapidly 1. The longer the exposure, the more conservative the taper should be.

Concurrent CNS Depressants

Exercise particular caution if the patient is taking opioids, benzodiazepines, or other CNS depressants concurrently, as withdrawal symptoms may be more pronounced and the sedative burden changes during taper 2, 3.

Common Pitfalls to Avoid

Do not abruptly discontinue pregabalin even from low doses like 50mg BID 3. The FDA label and clinical guidelines consistently emphasize gradual discontinuation over at least 1 week total 2, 3.

Do not assume a one-size-fits-all approach 2. Some patients tolerate 33% reductions well, while others require the more conservative 10-20% reductions every 1-2 weeks 1.

Do not ignore the return of original symptoms (pain, anxiety, seizures) during tapering, as this represents inadequate control of the underlying condition rather than withdrawal 2. If original symptoms worsen significantly, the taper may need to be slowed or the indication for discontinuation reconsidered.

Alternative Consideration

If the patient experiences significant withdrawal symptoms with the 75mg to 50mg reduction, consider an intermediate step of 75mg in the morning and 50mg in the evening (125mg/day total) for 1 week before proceeding to 50mg BID 2. This provides a more gradual 17% reduction followed by another 20% reduction.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Tapering Off Pregabalin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pregabalin: a new agent for the treatment of neuropathic pain.

Drugs of today (Barcelona, Spain : 1998), 2005

Related Questions

Can Lyrica (pregabalin) cause stuttering?
Does pregabalin (Lyrica) need to be tapered off when discontinuing its use?
Should a 38-year-old male patient's requests for orthotics insoles and Eucerin cream for skin care in pressure areas with Ankle-Foot Orthotics (AFO) be approved, considering his current regimen including Lyrica (pregabalin)?
Can Lyrica (pregabalin) cause mood swings?
What are the recommendations for a patient taking pregabalin (lyrica) with no current exercise routine to improve overall health and reduce fatigue?
What is the cause of shiny, almost metallic appearing light brown stools in a patient with a suspected mast cell disorder and normal qualitative fecal fat and elastase test results?
What is the recommended dose of minocycline (Minocycline) for a typical adult patient with a condition such as acne or an infection, considering their medical history, including any history of liver or kidney (Impaired renal function) disease?
What should an elderly male with significant weight loss, undiagnosed tremors, and elevated vitamin B12 levels do and which specialist should he see urgently?
Is potassium citrate a suitable treatment option for a patient with Restless Legs Syndrome (RLS)?
What is the best course of management for a 48-year-old male, status post right PCNL and open nephrolithotomy 13 days ago, presenting with fever, headache, left upper quadrant pain, hypotension, tachycardia, tachypnea, hyperthermia, leukocytosis, thrombocytopenia, and right-sided hydronephrosis?
What are the indications and considerations for a liver transplant in an adult patient with a history of liver disease, such as cirrhosis or liver cancer, who has not responded to previous treatments?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.